Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aritinercept aims to tame myasthenia gravis symptoms

NCT ID NCT07596901

Disease control Sponsor: Aurinia Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study tests a new drug, aritinercept, in 81 adults with generalized myasthenia gravis. The drug works by blocking two immune signals (BAFF and APRIL) to reduce disease activity. Researchers are checking if it is safe and if it improves daily living activities compared to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
aritinercept (a dual BAFF/APRIL inhibitor)
What this could lead to
If successful, this could lead to a new treatment option that helps control symptoms of generalized myasthenia gravis by targeting the immune system.
What could go wrong
This is an early Phase 1/2 trial with only 81 participants, so results are preliminary. The drug may not prove effective or could have side effects, and it is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 81 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Adult patients (18-85 years old) * Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG * Additional inclusion criteria are defined in the protocol Key Exclusion Criteria: * Current or medical history of malignancy within the last 5 years * Pregnant, breastfeeding or intending to become pregnant during the Study * Additional exclusion criteria are defined in the protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myasthenia gravis, generalized are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myasthenia gravis, generalized

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aurinia Investigational Site

    RECRUITING

    Pasadena, California, 91106, United States

  • Aurinia Investigational Site

    RECRUITING

    Altamonte Springs, Florida, 32714, United States

  • Aurinia Investigational Site

    RECRUITING

    Boca Raton, Florida, 33487, United States

  • Aurinia Investigational Site

    RECRUITING

    Homestead, Florida, 33033, United States

  • Aurinia Investigational Site

    RECRUITING

    Miami, Florida, 33155, United States

  • Aurinia Investigational Site

    RECRUITING

    Miami, Florida, 33173, United States

  • Aurinia Investigational Site

    RECRUITING

    Chicago, Illinois, 60616, United States

  • Aurinia Investigational Site

    RECRUITING

    O'Fallon, Illinois, 62269, United States

  • Aurinia Investigational Site

    RECRUITING

    Dearborn, Michigan, 48126, United States

  • Aurinia Investigational Site

    RECRUITING

    Flint, Michigan, 48507, United States

  • Aurinia Investigational Site

    RECRUITING

    Houston, Texas, 77027, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.